Navigation Links
AstraZeneca and UCL to collaborate to develop regenerative medicines for diabetic retinopathy
Date:9/13/2010

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

DR is now the most common cause of vision impairment among those of working age in Western society. The majority of patients with type 1 diabetes will develop retinopathy and about 20-30% will become blind. Moreover, a large number of patients with type 2 diabetes will develop retinopathy as their underlying disease progresses. With the global epidemic of type 2 diabetes, this predicament is set to worsen as over 438 million people are projected to suffer from diabetes and its complications by 2030.

Under the terms of the three-year agreement, AstraZeneca and scientists at the UCL Institute of Ophthalmology will collaborate to identify new therapeutic tools that can modulate the regenerative capacity of stem cells. Dr Marcus Fruttiger, UCL Institute of Ophthalmology, is leading the project and explains that, "These tools could be used either to manufacture transplantable material or to directly stimulate new cell growth in the eye to help restore or improve the vision of those with DR."

"AstraZeneca believes that regenerative medicine offers new opportunities to develop innovative, more effective and safer therapies to benefit patient health. Over the next few years, stem cell technology is likely to contribute to a measurable improvement in our ability to discover and develop candidate drugs, and to target those drugs to the right patient population through a better understanding of the disease process. We are delighted to be combining our drug hunting expertise with the pioneering research ongoing at UCL," said Alan Lamont, Director of Sciences and Technology Alliances at AstraZeneca .

Professor Pete Coffey, UCL Institute of Ophthalmology, adds: "This is a great collaborative opportunity and we're delighted to be working with AstraZeneca to explore the potential of harnessing the regenerative capacity of stem cells to develop a cellular therapy for diabetic retinopathy, which is a major cause of visual impairment and blindness worldwide. AstraZeneca has a proven track record in developing medicines and their involvement in this type of research is very exciting."


'/>"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-788-183-3274
University College London
Source:Eurekalert

Related medicine news :

1. AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
2. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
3. Gladstone and Lundbeck collaborate to study neurovascular disease
4. Anakam And Axolotl Collaborate To Deliver A Multi-Factor Authentication Platform For Santa Cruz Health Information Exchange
5. UCLA researchers, US military collaborate to open center for traumatic brain injury
6. Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution
7. Carefx to Collaborate with the Cleveland Clinic to Commercialize CCF Business Intelligence Solution
8. Two Hand Therapy Organizations Collaborate on Jam-Packed Educational Weekend
9. BCS Global and Iformata Sign Agreement to Collaborate on the PSVN Initiative to Deliver B2B Video Communications
10. PeopleStreme Collaborates with SkillSoft for Learning Management Content
11. Doctors must collaborate so that patients get full benefit of tamoxifen treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... In order to increase comfort, convenience ... a Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ , a ... the app, developed for both smartphones and personal computers perfectly emulates that of ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week 2016, ... over the United States to thank a nurse who's made a difference in their ... to the American Red Cross of San Diego/Imperial Counties (up to $10,000) every time ...
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... ... may not seem like an intuitive activity to alleviate the pain that’s a ... effective in improving pain and function in people with arthritis. , “Physical ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Chronic stress can ... constant presence, it can weaken the immune system and increase inflammation, both of which ... director of the adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic ...
(Date:5/5/2016)... Rochester, NY (PRWEB) , ... May 05, 2016 ... ... app is now available for iOS and Android devices. VisualDx is the ... expanded to include diagnostic support across general medicine. The system speeds diagnosis, ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology: